In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
After finishing at $7.59 in the prior trading day, Novavax, Inc (NASDAQ: NVAX) closed at $7.44, down -1.98%. In other words, the price has decreased by -$1.98 from its previous closing price. On the day, 5.04 million shares were traded. NVAX stock price reached its highest trading level at $7.64 during the session, while it also had its lowest trading level at $7.2801.
Ratios:
Our goal is to gain a better understanding of NVAX by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.24 and its Current Ratio is at 2.27.
BofA Securities Downgraded its Neutral to Underperform on August 20, 2025, while the target price for the stock was maintained at $7.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on May 19 ’25 when YOUNG JAMES F bought 10,000 shares for $7.59 per share.
YOUNG JAMES F bought 4,000 shares of NVAX for $24,406 on Apr 14 ’25. On Dec 13 ’24, another insider, King Rachel K., who serves as the Director of the company, sold 4,150 shares for $9.02 each. As a result, the insider received 37,435 and left with 14,770 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NVAX now has a Market Capitalization of 1208992512 and an Enterprise Value of 697238528. As of this moment, Novavax,’s Price-to-Earnings (P/E) ratio for their current fiscal year is 4.21, and their Forward P/E ratio for the next fiscal year is 39.18. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.14. Its current Enterprise Value per Revenue stands at 0.655 whereas that against EBITDA is 1.543.
Stock Price History:
The Beta on a monthly basis for NVAX is 2.30, which has changed by -0.17425084 over the last 52 weeks, in comparison to a change of 0.12121439 over the same period for the S&P500. Over the past 52 weeks, NVAX has reached a high of $11.55, while it has fallen to a 52-week low of $5.01. The 50-Day Moving Average of the stock is -11.33%, while the 200-Day Moving Average is calculated to be -1.90%.
Shares Statistics:
The stock has traded on average 5.68M shares per day over the past 3-months and 3871160 shares per day over the last 10 days, according to various share statistics. A total of 162.47M shares are outstanding, with a floating share count of 148.12M. Insiders hold about 8.85% of the company’s shares, while institutions hold 58.93% stake in the company. Shares short for NVAX as of 1760486400 were 45828036 with a Short Ratio of 8.07, compared to 1757894400 on 44723391. Therefore, it implies a Short% of Shares Outstanding of 45828036 and a Short% of Float of 28.32.
Earnings Estimates
Investors are eagerly awaiting the insights provided by 4.0 analysts currently analyzing and rating the stock of Novavax, Inc (NVAX).The consensus estimate for the next quarter is $0.06, with high estimates of $0.32 and low estimates of -$0.29.
Analysts are recommending an EPS of between $2.91 and $2.04 for the fiscal current year, implying an average EPS of $2.46. EPS for the following year is $0.3, with 7.0 analysts recommending between $3.87 and -$1.3.
Revenue Estimates
6 analysts predict $105.73M in revenue for. The current quarter. It ranges from a high estimate of $167M to a low estimate of $71M. As of. The current estimate, Novavax, Inc’s year-ago sales were $88.31MFor the next quarter, 6 analysts are estimating revenue of $114.68M. There is a high estimate of $166.3M for the next quarter, whereas the lowest estimate is $60.41M.
A total of 7 analysts have provided revenue estimates for NVAX’s current fiscal year. The highest revenue estimate was $1.14B, while the lowest revenue estimate was $1.05B, resulting in an average revenue estimate of $1.07B. In the same quarter a year ago, actual revenue was $682.16MBased on 9 analysts’ estimates, the company’s revenue will be $463.82M in the next fiscal year. The high estimate is $1.13B and the low estimate is $287.06M.
